AR044956A1 - Derivados de pirrolodihidroisoquinolinas, composiciones farmaceuticas que los contienen y su uso en el tratamiento del cancer. - Google Patents
Derivados de pirrolodihidroisoquinolinas, composiciones farmaceuticas que los contienen y su uso en el tratamiento del cancer.Info
- Publication number
- AR044956A1 AR044956A1 ARP040102290A ARP040102290A AR044956A1 AR 044956 A1 AR044956 A1 AR 044956A1 AR P040102290 A ARP040102290 A AR P040102290A AR P040102290 A ARP040102290 A AR P040102290A AR 044956 A1 AR044956 A1 AR 044956A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- amino
- halogen
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Abstract
Derivados de pirrolodihidroisoquinolina, que son inhibidores eficaces de (hiper) proliferación celular y/o inductores de apoptosis en células cancerosas. Reivindicación 1: Compuestos de la fórmula (1) caracterizados porque R1 es halógeno, nitro, amino, mono- o di-(alquil C1-4)amino, alquilo C1-4, ,hidroxilo, alcoxi C1-4, alcoxi C1-4-alcoxi-C2-4, cicloalcoxi C3-7, cicloalquilmetoxi C3-7 o alcoxi C1-4 completamente o predominantemente sustituido con F; R2 es H, halógeno o alcoxi C1-4, R3 es H o alcoxi C1-4, o R2 y R3 ligados al grupo anular benzo en posición orto entre si forman conjuntamente un puente alquilendioxi C1-2, o R2 y R3 ligados al grupo anular benzo en posición orto entre si forman conjuntamente un puente alquilendioxi C1-2 completamente o predominantemente sustituido con F, R1 y R2 ligados al grupo anular benzo en posición orto entre si forman conjuntamente un puente alquilendioxi C1-2 y R3 es H, o R1 y R2 ligados al grupo anular benzo en posición orto entre si forman conjuntamente un puente alquilendioxi C1-2 completamente o predominantemente sustituido con F y R3 es H; R4 es H, F, Cl. alquilo C1-4, trifluorometilo, ciclopropilo, ciano, alcoxicarbonilo C1-4 o -CH2-O-R411, donde R411 es H, alquilo C1-4, alcoxi C1-4-alquilo C2-4 o (alquil C1-4)carbonilo; R41 es H o alquilo C1-4; R5 es H; R51 es H; o R4 es H, F, Cl, o alquilo C1-4, R41 es H o alquilo C1-4; R5 es H; R51 es H; R6 es alquilo C1-6, amino, formilo o alquilo C1-4 sustituido con R61, donde R61 es (alcoxi C1-4)carbonilo, carboxilo, alcoxi C1-4, hidroxilo, halógeno o -N(R611)R612, donde R611 es H, alquilo C1-4, cicloalquilo C3-7 o cicloalquilo C3-7-alquilo C1-4; R612 es H o alquilo C1-4, o R611 y R612 conjuntamente y con la inclusión del átomo de N al cual están ligados forman un radical Het1, donde Het1 es un radical anular heterocíclico saturado de 5 a 7 miembros que comprende un átomo de N, al cual están ligados R611 y R612, y, opcionalmente, un heteroátomo adicional seleccionado del grupo formado por N, O y S, y opcionalmente sustituido con R613 sobre un átomo anular de N, donde R613 es alquilo C1-4, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-4, hidroxi-alquilo C2-4, alcoxi C1-4-alquilo C2-4, (alquil C2-4)amino, mono- o di-(alquil C1-4)amino-alquilo C2-4, formilo, piridilo o pirimidinilo; R7 es fenilo, Het2, fenilo sustituido con R71 y/o R72 y/o R73, Het2 sustituido con R74 y/o R75, naftilo o naftilo sustituido con R76 y/o R77, donde Het2 es un radical heteroarilo de5 a 10 miembros monocíclico o bicíclico fusionado que comprende 1 a 3 heteroátomos, cada uno de los cuales es seleccionado del grupo formado por N, O y S; R71 es hidroxilo, halógeno, nitro, ciano, trifluorometilo, alquilo C1-4, alcoxi C1-4, amino, mono- o di-(alquil C1-4)amino, alquil C1-4-sulfonilamino, arilsulfonilamino, (alcoxi C1-4)carbonilo, carboxilo, alquiltio C1-4, ariloxi-alcoxi C2-4, ariloxi-alquilo C1-4, ariloxi, aril-alcoxi C1-4, arilo, alcoxi C1-4-alcoxi C2-4, alcoxi C1-4-alquilo C1-4, hidroxi-alcoxi 2-4, amino-alcoxi C2-4, mono- o di-(alquil C1-4)amino-alcoxi C2-4 o alcoxi C1-4 completamente o predominantemente sustituido con F, donde arilo es fenilo o fenilo sustituido con R711, donde R711 es halógeno, alquilo C1-4, alcoxi C1-4, nitro o ciano, R72 es halógeno, alquilo C1-4, alcoxi C1-4 o (alcoxi C1-4)carbonilo; R73 es alquilo C1-4 o alcoxi C1-4; R74 es halógeno, alquilo C1-4, trifluorometilo, alcoxi C1-4, ciano, amino, mono- o di-(alquil C1-4)amino, (alcoxi C1-4)carbonilo, morfolino, carboxilo, nitro, fenilo o feniloxi; R75 es alquilo C1-4 o halógeno; R76 es halógeno, hidroxilo, alquilo C1-4, alcoxi C1-4,carboxilo o (alcoxi C1-4)carbonilo; R77 es alquilo C1-4 o alcoxi C1-4; R8 es fenilo, fenilcarbonilo, -C(O)-N(R82)R83 o -C(O)-OR9, donde R82 es H, alquilo C1-4, cicloalquilo C3-7, cicloalquilo C3-7-alquilo C1-4, fenilo o fenil-alquilo C1-4; R83 es H o alquilo C1-4, o R82 y R83 conjuntamente y con inclusión del átomo de N al cual están ligados, forman un radical anular heterocíclico seleccionado del grupo formado por pirrolidinilo, piperidinilo, morfolinilo o N-(alquil C1-4)-piperazinilo; R9 es alquilo C1-4; con la condición, que se excluye este subgrupo de compuestos de fórmula (1), en el cual se aplica la combinación de todas las restricciones a.) a c.) siguientes: a.) el esquema de sustitución del anillo benzo izquierdo sustituido con R1 y/o R2 y/o R3 del grupo dihidroisoquinolina de la estructura de la pirrolodihidroisoquinolina mostrada en la fórmula (1) es como se muestra en estructura (A) donde R´y R" pueden estar ligados a cualquier posición posible del anillo benzo, y R´ es hidroxilo, alcoxi C1-4 o trifluorometoxi, R" es H o alcoxi C1-4, o R´ y R" ligados al grupo anular benzo en posición orto entre sí forman conjuntamente un puente alquilendioxi C1-2, y b.) R4 es H, y R41 es H, y R5 es H, y R51 es H, y c.) R8 es -C(O)-OR9, donde R9 es alquilo C1-4; y las sales, estereoisómeros, hidratos e hidratos de las sales de estos compuestos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03014424 | 2003-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044956A1 true AR044956A1 (es) | 2005-10-12 |
Family
ID=33560746
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102290A AR044956A1 (es) | 2003-06-30 | 2004-06-30 | Derivados de pirrolodihidroisoquinolinas, composiciones farmaceuticas que los contienen y su uso en el tratamiento del cancer. |
ARP040102291A AR045696A1 (es) | 2003-06-30 | 2004-06-30 | Derivados de pirrolodihidroisoquinolinas como inhibidores de pde10 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102291A AR045696A1 (es) | 2003-06-30 | 2004-06-30 | Derivados de pirrolodihidroisoquinolinas como inhibidores de pde10 |
Country Status (22)
Country | Link |
---|---|
US (2) | US20060148840A1 (es) |
EP (2) | EP1641794A1 (es) |
JP (2) | JP2009513495A (es) |
KR (1) | KR20060030483A (es) |
CN (2) | CN1809564A (es) |
AR (2) | AR044956A1 (es) |
AT (1) | ATE478868T1 (es) |
AU (2) | AU2004253694A1 (es) |
BR (1) | BRPI0411897A (es) |
CA (2) | CA2530317A1 (es) |
DE (1) | DE602004028827D1 (es) |
EA (1) | EA012110B1 (es) |
IL (1) | IL171997A0 (es) |
IS (1) | IS8238A (es) |
MX (2) | MXPA05013822A (es) |
NO (1) | NO20060202L (es) |
NZ (1) | NZ544591A (es) |
RS (2) | RS20050945A (es) |
TW (2) | TW200510407A (es) |
UA (1) | UA86591C2 (es) |
WO (2) | WO2005003130A1 (es) |
ZA (2) | ZA200509267B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1641794A1 (en) * | 2003-06-30 | 2006-04-05 | ALTANA Pharma AG | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer |
WO2006075012A2 (en) * | 2005-01-12 | 2006-07-20 | Nycomed Gmbh | Pyrrolodihydroisoquinolines as antiproliferative agents |
DE602006006544D1 (de) * | 2005-01-12 | 2009-06-10 | Nycomed Gmbh | Neue pyrrolodihydroisochinoline als pde10-inhibitoren |
EP2063890A1 (en) | 2006-09-07 | 2009-06-03 | Nycomed GmbH | Combination treatment for diabetes mellitus |
ES2465216T3 (es) | 2007-06-04 | 2014-06-05 | Ben Gurion University Of The Negev Research And Development Authority | Compuestos de triarilo y composiciones que comprenden los mismos |
US7858620B2 (en) | 2007-09-19 | 2010-12-28 | H. Lundbeck A/S | Cyanoisoquinoline |
TW200918519A (en) * | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
TW200944523A (en) * | 2008-02-08 | 2009-11-01 | Organon Nv | (Dihydro)pyrrolo[2,1-a]isoquinolines |
KR20100121527A (ko) | 2008-02-29 | 2010-11-17 | 콘서트 파마슈티컬즈, 인크. | 치환된 잔틴 유도체 |
TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
US8133897B2 (en) | 2008-06-20 | 2012-03-13 | H. Lundbeck A/S | Phenylimidazole derivatives as PDE10A enzyme inhibitors |
UA102693C2 (ru) * | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Производные фенилимидазола как ингибиторы фермента pde10a |
US20110053961A1 (en) | 2009-02-27 | 2011-03-03 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
TWI461426B (zh) * | 2009-05-27 | 2014-11-21 | Merck Sharp & Dohme | (二氫)咪唑並異〔5,1-a〕喹啉類 |
TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑的2-芳基咪唑衍生物 |
TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物 |
TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之雜芳香族芳基三唑衍生物 |
TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
DE102010042833B4 (de) | 2010-10-22 | 2018-11-08 | Helmholtz-Zentrum Dresden - Rossendorf E.V. | Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung |
JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
WO2012112946A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
WO2013013052A1 (en) | 2011-07-19 | 2013-01-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
WO2013045607A1 (en) | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
AR089361A1 (es) | 2011-12-21 | 2014-08-20 | Lundbeck & Co As H | Derivados de quinolina como inhibidores de la enzima pde10a |
WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
CN103059029B (zh) * | 2012-12-28 | 2014-12-10 | 塔里木大学 | 一种六氢吡咯[2,3]并吲哚类化合物及其制备方法和在杀菌活性中的应用 |
CN105531272B (zh) * | 2013-07-25 | 2017-12-22 | 雅盖隆大学 | 作为5‑ht6拮抗剂的吡咯并喹啉衍生物、其制备方法和用途 |
CR20160207A (es) | 2013-11-05 | 2016-08-10 | Ben Gurion Univ Of The Negev Res And Dev Authority | Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
WO2015160913A1 (en) | 2014-04-18 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Methods of treating hyperglycemia |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE690792A (es) * | 1966-12-07 | 1967-05-16 | ||
DE3401018A1 (de) * | 1984-01-13 | 1985-07-18 | Boehringer Ingelheim KG, 6507 Ingelheim | Verfahren zur herstellung von 5,6-dihydro-pyrrolo(2,1-a)isochinolinen |
FR2761358B1 (fr) * | 1997-03-27 | 1999-05-07 | Adir | Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CA2431326A1 (en) * | 2000-12-13 | 2002-06-20 | Bayer Aktiengesellschaft | Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors |
IL149106A0 (en) * | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
US20030018047A1 (en) * | 2001-04-20 | 2003-01-23 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
DE10130151A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Neue Verwendung für PDE 10A-Inhibitoren |
US20030236276A1 (en) * | 2001-08-06 | 2003-12-25 | Ulrich Niewohner | Pyrrolo[2.1-a]isoquinoline derivatives |
WO2003014115A1 (en) * | 2001-08-06 | 2003-02-20 | Bayer Aktiengesellschaft | 3-substituted pyrrolo (2.1-a) isoquinoline derivatives |
WO2003051877A1 (en) * | 2001-12-18 | 2003-06-26 | Bayer Corporation | 2-substituted pyrrolo[2.1-a]isoquinolines against cancer |
EP1641794A1 (en) * | 2003-06-30 | 2006-04-05 | ALTANA Pharma AG | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer |
DE602006006544D1 (de) * | 2005-01-12 | 2009-06-10 | Nycomed Gmbh | Neue pyrrolodihydroisochinoline als pde10-inhibitoren |
WO2006075012A2 (en) * | 2005-01-12 | 2006-07-20 | Nycomed Gmbh | Pyrrolodihydroisoquinolines as antiproliferative agents |
-
2004
- 2004-06-30 EP EP04766106A patent/EP1641794A1/en not_active Withdrawn
- 2004-06-30 CN CNA2004800175104A patent/CN1809564A/zh active Pending
- 2004-06-30 WO PCT/EP2004/051315 patent/WO2005003130A1/en active Application Filing
- 2004-06-30 CA CA002530317A patent/CA2530317A1/en not_active Abandoned
- 2004-06-30 RS YUP-2005/0945A patent/RS20050945A/sr unknown
- 2004-06-30 AU AU2004253694A patent/AU2004253694A1/en not_active Abandoned
- 2004-06-30 MX MXPA05013822A patent/MXPA05013822A/es unknown
- 2004-06-30 UA UAA200600505A patent/UA86591C2/ru unknown
- 2004-06-30 EP EP04741932A patent/EP1641792B1/en active Active
- 2004-06-30 DE DE602004028827T patent/DE602004028827D1/de active Active
- 2004-06-30 CN CNA2004800175231A patent/CN1809565A/zh active Pending
- 2004-06-30 AU AU2004253690A patent/AU2004253690B2/en not_active Ceased
- 2004-06-30 NZ NZ544591A patent/NZ544591A/xx unknown
- 2004-06-30 JP JP2006516198A patent/JP2009513495A/ja active Pending
- 2004-06-30 RS YUP-2005/0946A patent/RS20050946A/sr unknown
- 2004-06-30 AR ARP040102290A patent/AR044956A1/es not_active Application Discontinuation
- 2004-06-30 BR BRPI0411897-9A patent/BRPI0411897A/pt not_active IP Right Cessation
- 2004-06-30 TW TW093119589A patent/TW200510407A/zh unknown
- 2004-06-30 EA EA200501928A patent/EA012110B1/ru not_active IP Right Cessation
- 2004-06-30 CA CA002530316A patent/CA2530316A1/en not_active Abandoned
- 2004-06-30 AR ARP040102291A patent/AR045696A1/es not_active Application Discontinuation
- 2004-06-30 TW TW093119579A patent/TW200510413A/zh unknown
- 2004-06-30 JP JP2006516197A patent/JP2009513494A/ja active Pending
- 2004-06-30 US US10/562,137 patent/US20060148840A1/en not_active Abandoned
- 2004-06-30 US US10/562,149 patent/US20060148838A1/en not_active Abandoned
- 2004-06-30 MX MXPA05013553A patent/MXPA05013553A/es active IP Right Grant
- 2004-06-30 WO PCT/EP2004/051307 patent/WO2005003129A1/en active Application Filing
- 2004-06-30 KR KR1020057024872A patent/KR20060030483A/ko not_active Application Discontinuation
- 2004-06-30 AT AT04741932T patent/ATE478868T1/de not_active IP Right Cessation
-
2005
- 2005-11-16 ZA ZA200509267A patent/ZA200509267B/en unknown
- 2005-11-16 ZA ZA200509265A patent/ZA200509265B/en unknown
- 2005-11-16 IL IL171997A patent/IL171997A0/en unknown
-
2006
- 2006-01-13 NO NO20060202A patent/NO20060202L/no not_active Application Discontinuation
- 2006-01-18 IS IS8238A patent/IS8238A/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR044956A1 (es) | Derivados de pirrolodihidroisoquinolinas, composiciones farmaceuticas que los contienen y su uso en el tratamiento del cancer. | |
AR079131A1 (es) | Derivados de naftiridina y el uso de los mismos como inhibidores de quinasa | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR033686A1 (es) | Nuevos derivados de n-(arilsulfonil)beta-aminoacidos que comprenden un grupo aminometilo substituido, su preparacion, y las composiciones farmaceuticas que los contienen | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
PE20091371A1 (es) | Inhibidores de hsp90 | |
AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
PE20181024A1 (es) | Derivados de ciclohexano sustituido con amido | |
AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
AR081978A1 (es) | Derivados fusionados de pirimidina para la inhibicion de la actividad quinasa de tirosina | |
AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
AR095430A1 (es) | Compuestos de pirimidina y piridina y su uso como inhibidores de la actividad de fgfr | |
AR055361A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
AR043063A1 (es) | Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas | |
AR040567A1 (es) | Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6 | |
AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
AR051753A1 (es) | Metodos para preparar compuestos de indazol | |
CY1114319T1 (el) | Νεες υδροξυ-6-ετεροαρυλφαινανθριδινες και χρηση αυτων ως αναστολεις pde4 | |
AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
ES2582306T3 (es) | Derivados de morfinano que contienen un grupo carboxamida como ligandos de receptores opioides | |
AR112468A1 (es) | Carboxamidas como inhibidores de proteasa específicos de ubiquitina | |
CO5601021A2 (es) | Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb | |
AR052370A1 (es) | Tiazolidinonas y su uso como inhibidores de la poloquinasa(plk) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |